Antibiotic effectiveness: Balancing conservation against innovation

Antibiotic effectiveness is a natural societal resource that is diminished by antibiotic use. As with other such assets, keeping it available requires both conservation and innovation. Conservation encompasses making the best use of current antibiotic effectiveness by reducing demand through vaccination, infection control, diagnostics, public education, incentives for clinicians to prescribe fewer antibiotics, and restrictions on access to newer, last-resort antibiotics. Innovation includes improving the efficacy of current drugs and replenishing effectiveness by developing new drugs. In this paper, I assess the relative benefits and costs of these two approaches to maintaining our ability to treat infections.

[1]  A. Kesselheim,et al.  Approval and Withdrawal of New Antibiotics and other Antiinfectives in the U.S., 1980–2009 , 2013, Journal of Law, Medicine & Ethics.

[2]  A. Russell,et al.  Biocide use and antibiotic resistance: the relevance of laboratory findings to clinical and environmental situations. , 2003, The Lancet. Infectious diseases.

[3]  J. Dushoff,et al.  Antibiotic overuse: the influence of social norms. , 2008, Journal of the American College of Surgeons.

[4]  H. Goossens,et al.  Achievements of the Belgian Antibiotic Policy Coordination Committee (BAPCOC). , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[5]  Tara C Smith,et al.  Isolation and Characterization of Methicillin-Resistant Staphylococcus aureus from Pork Farms and Visiting Veterinary Students , 2013 .

[6]  Bryan T Grenfell,et al.  Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. , 2014, The Lancet. Infectious diseases.

[7]  K. Arrow,et al.  From Financing to Fevers: Lessons of an Antimalarial Subsidy Program , 2012, Science.

[8]  W. Schaffner,et al.  Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. , 2006, The New England journal of medicine.

[9]  B. Fantin,et al.  Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. , 2009, The Journal of infectious diseases.

[10]  I. Okeke,et al.  Non-prescription antimicrobial use worldwide: a systematic review. , 2011, The Lancet. Infectious diseases.

[11]  P. Böelle,et al.  Significant Reduction of Antibiotic Use in the Community after a Nationwide Campaign in France, 2002–2007 , 2009, PLoS medicine.

[12]  R. Capita,et al.  Exposure of Escherichia coli ATCC 12806 to Sublethal Concentrations of Food-Grade Biocides Influences Its Ability To Form Biofilm, Resistance to Antimicrobials, and Ultrastructure , 2013, Applied and Environmental Microbiology.

[13]  Thierry Naas,et al.  Global Spread of Carbapenemase-producing Enterobacteriaceae , 2011, Emerging infectious diseases.

[14]  A Forrest,et al.  Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients , 2011, Antimicrobial Agents and Chemotherapy.

[15]  H. Goossens,et al.  Characteristics and outcomes of public campaigns aimed at improving the use of antibiotics in outpatients in high-income countries. , 2010, The Lancet. Infectious diseases.

[16]  M. Wilcox,et al.  Once-weekly dalbavancin versus daily conventional therapy for skin infection. , 2014, The New England journal of medicine.

[17]  W. O'Riordan,et al.  Single-dose oritavancin in the treatment of acute bacterial skin infections. , 2014, The New England journal of medicine.

[18]  B. Munoz,et al.  Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control. , 2014, International journal of epidemiology.

[19]  S. Salmaso,et al.  National seasonal influenza vaccination survey in Europe, 2008. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[20]  R. Laxminarayan.  Extending the Cure: Policy Responses to the Growing Threat of Antibiotic Resistance , 2007 .

[21]  Gardner M. Brown,et al.  Economics of Antibiotic Resistance: A Theory of Optimal Use , 2001 .

[22]  L. Price,et al.  Livestock-Associated Methicillin and Multidrug Resistant Staphylococcus aureus Is Present among Industrial, Not Antibiotic-Free Livestock Operation Workers in North Carolina , 2013, PloS one.

[23]  R. Betts,et al.  Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. , 2013, JAMA.

[24]  T. Lauderdale,et al.  Competing Doctors , Antibiotic Use , and Antibiotic Resistance in Taiwan ∗ , 2008 .

[25]  H. Goossens,et al.  Antibiotic resistance—the need for global solutions , 2013, BDJ.

[26]  T. Quinn,et al.  Azithromycin in control of trachoma , 1999, The Lancet.

[27]  M. Cooper,et al.  Antibiotics in the clinical pipeline in 2013 , 2013, The Journal of Antibiotics.

[28]  V. Diwan,et al.  Association between health insurance and antibiotics prescribing in four counties in rural China. , 1999, Health policy.

[29]  H. Goldbach,et al.  Antibiotics as part of the management of severe acute malnutrition. , 2013, The New England journal of medicine.

[30]  U. Theuretzbacher,et al.  Future antibiotics scenarios: is the tide starting to turn? , 2009, International journal of antimicrobial agents.

[31]  I. Okeke,et al.  Antimicrobial resistance in developing countries. Part II: strategies for containment. , 2005, The Lancet. Infectious diseases.